PARP inhibitors: Clinical utility and possibilities of overcoming resistance - ScienceDirect
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Discussion of PARP inhibitors in cancer therapy | Pharmaceutical Patent Analyst
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors | Bentham Science
PARP inhibitors: Treating mCRPC from a genetic basis
Effects of pharmacologic PARP inhibition in B16F10 melanoma cells.... | Download Scientific Diagram
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions | British Journal of Cancer
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
Mechanism of Action of PARP Inhibitors. Note: in the presence of a PARP... | Download Scientific Diagram
Role of PARP Inhibitors in BRCA-Related Malignancies
How Do PARP Inhibitors Work In Cancer? | Dana-Farber Cancer Institute
An update on PARP inhibitors—moving to the adjuvant setting | Nature Reviews Clinical Oncology
Advances and perspectives of PARP inhibitors | Experimental Hematology & Oncology | Full Text
Niraparib is an Orally Active PARP Inhibitor - Network of Cancer Research
PARP Inhibition | PARP Inhibitor Review
Cancers | Free Full-Text | PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells: Trends in Cell Biology
PARP inhibitor - Wikipedia
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect
PARP inhibitors in cancer treatment | OncologyPRO
Biomedicines | Free Full-Text | Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
